Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt(University of British Columbia), Kim N.(BC Cancer Agency), Brian McConeghy(University of British Columbia), Matti Annala(Tampere University), Colin C. Collins(University of British Columbia), Anne Haegert(University of British Columbia), Martin Gleave(University of British Columbia), Matti Nykter(University of Liverpool), Robert Shukin(University of British Columbia), Stanislav Volik(University of British Columbia), Arun Azad(Novartis (Switzerland)), Stéphane Le Bihan(University of British Columbia), Evan W. Warner(Guardant (United States)), Sonal Brahmbhatt(University of British Columbia), Fan Mo(University of British Columbia), Kevin Beja(University of British Columbia)
Cited by 384
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Antisense therapy for cancer
|Nature reviews. Cancer|2005|399